{"prompt": "['Alliance A171601', 'composite endpoint. OTU combines clinical efficacy (\"Is my patient alive without disease', 'progression?\"), clinical tolerability (\"Did we avoid causing major harm\"), and patient', 'opinion (\"Was my treatment worthwhile and acceptable?\"). In the original study using OTU,', 'the composite endpoint was found to be particularly useful when conventional outcomes', 'were divergent (Oxaliplatin improved response rates and progression free survival, yet', 'resulted in increased toxicity), and helped confirm the benefit of Oxaliplatin5 We will', 'measure OTU by assessing clinical benefit and tolerability/acceptability at the end of', 'treatment. (See Study calendar Section 5.0 and AppendixIV). OTU: is scored as Good OTU', '(clinical or radiographic evidence or disease progression, no major negative treatment', 'effects in terms of toxicity or patient acceptability), Intermediate OTU (either clinical', 'deterioration but no negative treatment effect, or a significant negative treatment effect but', 'no clinical deterioration), or Poor OTU (both clinical deterioration and a major negative', 'treatment effect, or death).', '11.1.3 Was it worth it questionnaire', 'The Was It Worth It instrument (Appendix III) was developed to learn more about the', 'experience of patients participating in clinical trials. It is comprised of four brief questions,', 'and it has also been called the \"Trial Satisfaction\" survey. 58 Although formal validity and', 'reliability data for this instrument are not yet available, multiple cooperative group studies', 'have used it to measure how satisfied patients end up with their decision to enroll on a', 'clinical trial. 59-63', '11.1.4. Quality of life', 'All participants-will be asked to fill out a short QOL survey and on paper at each provider', 'assessment visit at baseline through the start of cycle 6 (unless patients come off study', 'treatment before that time). Appendix V has the required EQ-5D-3L survey.)', '11.1.5 Adherence evaluation', 'Pill diaries will be collected at the end of each cycle of treatment to ascertain dose delivered', 'adherence to palbociclib for a maximum of three cycles from initiation of protocol', 'treatment. Adherence to palbociclib will be measured by patient self-report in dedicated', 'patient diaries. (Appendix VII). Patients will be asked to bring their pill diaries to every', 'clinic visit.', '11.2 Measurement of tumor response and schedule of evaluations', 'Response and progression will be evaluated in this study using the new international criteria', 'proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guidelines', '(version 1.1).', 'Per the new RECIST criteria, as disease response is not the primary endpoint of this trial,', 'confirmatory scans following documentation of progression or response will not be required', 'Rather, progression/response will be determined based on results of the single scan.', 'Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the', 'short axis measurements in the case of lymph nodes are used in the RECIST guideline. 64', 'Schedule of Evaluations', 'For the purposes of this study, patients should be reevaluated for tumor response every 12 weeks.', 'While on study, a CT of the chest, abdomen, with or without pelvis (or PET-CT as above) will', 'be performed every 12 weeks (2 weeks). A bone scan will be done at restaging time points if', 'clinically indicated (or to confirm a complete response).', '50', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', 'Toxicity Evaluation', 'Toxicity evaluations will be performed Days 1 (2 days), 8 (+2 days), and 15 (=2 days) of Cycles', '1 and 2. For subsequent cycles, toxicity evaluations will be done on Day 1 (+2 days). Additional', 'adverse events captured in-between will also be recorded. (Please see study calendar Section', '5.0)', 'All toxicity related dose interruptions or reductions, hospitalizations, and adverse events will be', 'noted. Patients will be followed for toxicity outcomes for an additional 30 days after stopping', 'the drug and until resolution of all grade >2 toxicities. Any toxicities will be recorded in the', \"patient's medical record and highest grade of that toxicity will be reported on the case report\", 'forms.', '11.3 Definitions of Measurable and Non-Measurable Disease', '11.3.1 Measurable Disease', 'Measurable lesions are defined as those that can be accurately measured in at least one', 'dimension (longest diameter to be recorded) as > 10mm with conventional techniques (CT,', 'or caliper measurement). Lymph nodes greater than 15mm on short axis are considered', 'measurable as well. All tumor measurements must be recorded in millimeters (or decimal', 'fractions of centimeters).', 'Tumor lesions in a previously irradiated area are not considered measurable disease.', '11.3.2 Non-Measurable Disease', 'All other lesions (or sites of disease), are considered non-measurable disease.', 'Organomegaly, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis', 'cutis/pulmonis, inflammatory breast disease, and abdominal masses (not followed by CT', 'are all non-measurable.', 'Target lesions: All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions', 'in total, representative of all involved organs, should be identified as target lesions and', 'recorded and measured at baseline. Lymph nodes less than 15mm in the short axis cannot', 'be used as target lesions. Target lesions should be selected on the basis of their size (lesions', 'with the longest diameter) and their suitability for accurate repeated measurements (either', 'by imaging techniques or clinically). A sum of the longest diameter (LD) for all target', 'lesions will be calculated and reported as the baseline sum LD. The baseline sum LD will', 'be used as reference by which to characterize the objective tumor response.', 'Non-target lesions: All other lesions (or sites of disease) including any measurable lesions', 'over and above the 5 target lesions should be identified as non-targetlesions and should', 'also be recorded at baseline. Measurements of these lesions are not required, but the', 'presence or absence of each should be noted throughout follow-up', 'All other lesions (or sites of disease) are considered non-measurable disease, including', 'pathological nodes (those with a short axis > 1.0 to < 1.5cm). Bone lesions, leptomeningeal', 'disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory', 'breast disease, and abdominal masses (not followed by CT), are considered as non-', 'measurable as well.', 'Note: \"Cystic lesions\\' thought to represent cystic metastases can be considered as', 'measurable lesions, if they meet the definition of measurability described above. However,', 'if non-cystic lesions are present in the same patient, these are preferred for selection as target', 'lesions. In addition, lymph nodes that have a short axis < 1.0 cm are considered non-', 'pathological (i.e., normal) and should not be recorded or followed.', '51', 'NCI Version Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}